Retatrutide
Retatrutide (LY3437943) — GLP-1 / GIP / glucagon triple agonist for metabolic research.
Add 2 more to unlock 17% off
Questions? Reach us directly. Message on WhatsApp (Business Mobile — avg 1-hr response) or email admin@dmvresearch.shop.
For in-vitro and pre-clinical research use only. Not for human consumption, therapeutic use, or veterinary application. Research Use Only Policy
Free shipping
On orders over $150
Damage protection
Replacement on broken vials
Secure checkout
256-bit SSL
Compound Information
Updated 2026-06-08Technical specifications
A synthetic triple-agonist research peptide with activity at GLP-1, GIP, and glucagon receptors. Investigated in pre-clinical and Phase 2/3 metabolic-research models exploring combined incretin and glucagon-receptor signaling.
What Is Retatrutide?
- Type
- Synthetic Peptide
- CAS Number
- 2381089-83-2
- Molecular Weight
- 4,731 g/mol
- Amino Acids
- 39
- Fatty Acid Chain
- C20 diacid
- Primary Target
- GLP-1R, GIPR, GCGR (triple-agonist)
Stability Information
Lyophilized (powder)
-20°C· stable
Reconstituted
2–8°C· use within 30 days
Triple-Receptor Agonism
Simultaneous activation of three hormone receptors
Research Outcomes
Dosing in Clinical Studies
Protocols from published peer-reviewed trials. Provided for educational reference only — not prescribing guidance.
| Protocol | Dose | Route | Frequency | Indication (Research) |
|---|---|---|---|---|
| Phase 2 Obesity Trial (NEJM 2023) | 0.5 mg → 4 mg, 8 mg, or 12 mg (dose escalation) | Subcutaneous injection | Once weekly | Obesity / excess adiposity research model |
| Phase 2 Type 2 Diabetes Trial (Lancet 2023) | 0.5 mg → up to 12 mg (dose escalation) | Subcutaneous injection | Once weekly | Type 2 diabetes glycemic research model |
| MASLD Sub-study (Nature Medicine 2024) | 4 mg or 8 mg (maintenance) | Subcutaneous injection | Once weekly for 48 weeks | Metabolic dysfunction-associated steatotic liver disease research |
Sources & References
10 sources · research references
New England Journal of Medicine
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023
Jastreboff AM, et al.
The Lancet
Retatrutide for People with Type 2 Diabetes — A Phase 2 Trial
2023
Rosenstock J, et al.
Nature Medicine
Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024
Sanyal AJ, et al.
Biomolecules
Retatrutide — A Game Changer in Obesity Pharmacotherapy
2025
Katsi V, et al.
Diabetes, Obesity and Metabolism
Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis: TRIUMPH Trial Design
2026
Giblin K, et al.
The Lancet Diabetes & Endocrinology
Effects of Retatrutide on Body Composition in People with Type 2 Diabetes: A Substudy of a Phase 2 Randomised Trial
2025
Coskun T, Wu Q, Schloot NC, et al.
Cell Metabolism
LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept
2022
Coskun T, et al.
Nature Medicine
A Monomeric GLP-1/GIP/Glucagon Triagonist Treats Obesity in Rodents and Primates
2015
Finan B, et al.
ClinicalTrials.gov
TRIUMPH Phase 3 Clinical Trial Program — Retatrutide for Obesity, Sleep Apnea, and Related Conditions
2024
PubChem Database
Retatrutide Compound Information
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations. See our Research Use Only policy.
Certificate of Analysis
Third-party HPLC purity testing for this compound. Download the full-resolution certificates below.
Independently HPLC-tested for identity, purity, and concentration.
